2025
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
Foss F, Kim Y, Scarisbrick J, Akilov O, Ristuccia R, Dwyer K, Wu W, Bagot M. Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. Journal Of Dermatological Treatment 2025, 36: 2438794. PMID: 39894454, DOI: 10.1080/09546634.2024.2438794.Peer-Reviewed Original ResearchConceptsMogamulizumab-associated rashConcomitant steroid useSezary syndromeAdvanced diseaseMycosis fungoidesSteroid useResponse to mogamulizumabProportion of patientsPercentage of patientsTreatment of patientsConcomitant steroidsRelapsed/refractory patientsLong-term responseMogamulizumabNext treatmentPatient characteristicsPatientsLymphopeniaVorinostatPatient responseFungoidesPFSMycosisSyndromeTreatmentIncidence of Surgery for Pediatric Wrist Ganglion Cysts.
Rancu A, Kammien A, Katsnelson B, Diatta F, Lewis K, Grauer J, Colen D. Incidence of Surgery for Pediatric Wrist Ganglion Cysts. Hand 2025, 15589447251314142. PMID: 39891524, PMCID: PMC11787722, DOI: 10.1177/15589447251314142.Peer-Reviewed Original ResearchWrist ganglion cystsGanglion cystYears of follow-upIncidence of surgeryPercentage of patientsNationwide analysisStatistically significant differenceMagnetic resonance imagingNonoperative managementSurgical managementPearlDiver databaseDiagnosis of ganglion cystPediatric populationFollow-upSurgical planningPatient counselingSurgeryPatientsExclusion criteriaResonance imagingFirst diagnosisCystsSignificant differenceDiagnosis codesDiagnosis
2024
Detection, Patterns, and Outcomes of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Shah R, Wilkins S, Safranek C, Shah H, Brophy C, Mehra S. Detection, Patterns, and Outcomes of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head & Neck Surgery 2024, 150: 1105-1112. PMID: 39418066, PMCID: PMC11581730, DOI: 10.1001/jamaoto.2024.3237.Peer-Reviewed Original ResearchHPV-positive oropharyngeal squamous cell carcinomaOropharyngeal squamous cell carcinomaSquamous cell carcinomaDistant metastasisDisease recurrenceCell carcinomaRecurrence detectionHuman papillomavirus (HPV)-positive oropharyngeal squamous cell carcinomaCohort studyMethod of recurrence detectionSurveillance strategiesSurveillance imaging strategiesLocation of recurrencePatterns of recurrenceFollow-up timeElectronic medical record reviewOptimal surveillance strategyPercentage of patientsRetrospective cohort studyIncidence of DMTertiary care hospitalDiagnosis to deathMedical record reviewRecurrence cohortRegional recurrenceUtilization and Duration of Systemic Corticosteroid Exposure in Atopic Dermatitis Patients After the Introduction of Advanced Therapies: A Population-Based Study From the United States
Bunick C, Vleugels R, Lebwohl M, Grada A, Yue E, Wegrzyn L, D'Andrea E. Utilization and Duration of Systemic Corticosteroid Exposure in Atopic Dermatitis Patients After the Introduction of Advanced Therapies: A Population-Based Study From the United States. SKIN The Journal Of Cutaneous Medicine 2024, 8: s448. DOI: 10.25251/skin.8.supp.448.Peer-Reviewed Original ResearchSystemic corticosteroid treatmentSystemic corticosteroidsAtopic dermatitisLong-term usersAdvanced therapiesContinuous health insurance enrollmentUsage of non-steroidal anti-inflammatory drugsRelevant proportion of patientsManagement of atopic dermatitisOral systemic corticosteroidsSystemic corticosteroid exposureClinical guidelinesHistory of malignancyProportion of patientsImmuno-mediated diseasesNon-steroidal anti-inflammatory drugsPercentage of patientsAtopic dermatitis patientsIntroduction of advanced therapiesAdvanced systemic treatmentsPopulation-based studyAnti-inflammatory drugsShort-term usersPrescription of biologicsCorticosteroid exposureSpesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial
Gottlieb A, Strober B, Merola J, Mostaghimi A, Farberg A, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s490. DOI: 10.25251/skin.8.supp.490.Peer-Reviewed Original ResearchGeneralized pustular psoriasisPhysician global assessmentSkin symptomsPustular psoriasisGlobal assessmentProportion of patientsPercentage of patientsTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsClear skinSpesolimabPatientsContinuous treatmentMonoclonal antibodiesSkin diseasesPatient burdenSymptomsPsoriasisTotal scoreSkinTreatmentIn a cohort of 961 clinically suspected Duchenne muscular dystrophy patients, 105 were diagnosed to have other muscular dystrophies (OMDs), with LGMD2E (variant SGCB c.544A>C) being the most common
Karthikeyan P, Kumar S, Khanna‐Gupta A, Raman L. In a cohort of 961 clinically suspected Duchenne muscular dystrophy patients, 105 were diagnosed to have other muscular dystrophies (OMDs), with LGMD2E (variant SGCB c.544A>C) being the most common. Molecular Genetics & Genomic Medicine 2024, 12: e2123. PMID: 39548682, PMCID: PMC11568062, DOI: 10.1002/mgg3.2123.Peer-Reviewed Original ResearchConceptsLimb-girdle muscular dystrophyDuchene muscular dystrophyMuscular dystrophyDuchenne muscular dystrophy patientsPercentage of patientsAutosomal recessive diseaseMuscular dystrophy patientsCharcot Marie ToothNegative patientsCongenital myopathiesDeletion/duplication analysisNext generation sequencing analysisDiagnosed patientsDystrophy patientsRecessive diseaseSevere formPatientsDystrophyLimb girdlesGenetic variantsPrevention strategiesVariant casesPoint mutationsSGCB geneFounder effectAtrasentan in Patients with IgA Nephropathy
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, Zhang H, Lodha A, Gray T, Wang Y, Renfurm R, Barratt J. Atrasentan in Patients with IgA Nephropathy. New England Journal Of Medicine 2024, 392: 544-554. PMID: 39460694, DOI: 10.1056/nejmoa2409415.Peer-Reviewed Original ResearchIgA nephropathyAdverse eventsInterim analysisBiopsy-proven IgA nephropathyInterim analysis of dataBaseline to weekBody-surface areaPercentage of patientsProtein-to-creatinine ratioUrinary protein-to-creatinine ratioMean percentage changeCases of cardiac failureRisk of kidney failureClinically meaningful reductionsTrial regimenPlacebo groupAntagonist atrasentanDouble-blindBetween-group differencesCardiac failureReduce proteinuriaFluid retentionSevere proteinuriaAtrasentan groupAtrasentanA comparison of steroid dose with or without local anesthetic in lumbar interlaminar epidural steroid injections
Chow R, Ng J, Wood M, Yanez D, He Z, Rajput K. A comparison of steroid dose with or without local anesthetic in lumbar interlaminar epidural steroid injections. Pain Practice 2024, 25: e13410. PMID: 39305041, DOI: 10.1111/papr.13410.Peer-Reviewed Original ResearchEpidural steroid injectionsHigh-dose steroidsInterlaminar epidural steroid injectionsLow-dose steroidsInterlaminar ESILow-dose dexamethasonePercentage of patientsPain reliefSteroid injectionMonths follow-upLocal anestheticsSteroid doseLumbar interlaminar epidural steroid injectionsTransforaminal epidural steroid injectionPercentage of pain reliefHigh-dose dexamethasoneModerate to significant improvementNRS pain scoresSignificant pain improvementSignificant pain reliefNon-particulate steroidsBaseline demographic dataTransforaminal ESILumbar radiculopathyPain improvementMDS-156 Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMerge
Zeidan A, Santini V, Platzbecker U, Sekeres M, Savona M, Fenaux P, Madanat Y, Raza A, Xia Q, Sun L, Riggs J, Shah S, Navada S, Berry T, Komrokji R. MDS-156 Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMerge. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s386. DOI: 10.1016/s2152-2650(24)01344-2.Peer-Reviewed Original ResearchLower-risk myelodysplastic syndromesMyeloid growth factorsErythropoiesis-stimulating agentsRBC-TIPlatelet transfusionsTransfusion-dependentHb levelsLong-term respondersPercentage of patientsHb riseRBC-TDPlacebo patientsNon-del(5qMyelodysplastic syndromePlacebo groupPrimary endpointSecondary endpointsInvestigator's discretionClinical benefitPlaceboAnalysis cutoffImetelstatDisease progressionTransfusionSupportive careP116. National trends and risk factors for new-onset depression following posterior lumbar fusion
Day W, Gouzoulis M, Zhu J, Seddio A, Fourman M, Grauer J. P116. National trends and risk factors for new-onset depression following posterior lumbar fusion. The Spine Journal 2024, 24: s119. DOI: 10.1016/j.spinee.2024.06.138.Peer-Reviewed Original ResearchNew-onset depressionPosterior lumbar fusionNational administrative claims databaseSingle-level posterior lumbar fusionRisk factorsDevelopment of new-onset depressionAdministrative claims databasePostoperative complicationsLumbar fusionNational trendsFactors associated with patientsClaims databaseAggregate patient dataAdult patientsTarget risk mitigation strategiesMultivariate logistic regressionPsychiatric risk factorsPotential risk factorsElixhauser Comorbidity IndexPercentage of patientsHigher oddsCase-controlAlcohol/drug abuseDiagnosis of tumorsLogistic regressionImpact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY
Wiedemann M, Speed V, Cunningham C, Higgins R, Curtis H, Andrews C, Fisher L, Hopcroft L, Rentsch C, Mahalingasivam V, Tomlinson L, Morton C, Samuel M, Green A, Wood C, Brown A, Massey J, Walters C, Smith R, Inglesby P, Evans D, Maude S, Dillingham I, Walker A, Morley J, Mehrkar A, Bacon S, Bates C, Cockburn J, Parry J, Hester F, McManus R, Goldacre B, MacKenna B. Impact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY. Open Heart 2024, 11: e002732. PMID: 39214534, PMCID: PMC11664366, DOI: 10.1136/openhrt-2024-002732.Peer-Reviewed Original ResearchConceptsBlood pressure screeningPressure screeningPercentage of patientsHypertension prevalenceHypertension managementPopulation-based cohort studyRecord of hypertensionCardiovascular disease managementClinical subgroupsQOF indicatorsScreening ratesPrimary careGeneral practiceHome statusNHS patientsOlder peopleBlood pressure measurementsCare schemesCohort studyDisease managementImpact of COVID-19COVID-19Framework indicatorsNational qualityNHSAssociation of Race and Ethnicity with Prescriptions for Continuous Glucose Monitoring Systems Among a National Sample of Veterans with Diabetes on Insulin Therapy
Lipska K, Oladele C, Zawack K, Gulanski B, Mutalik P, Reaven P, Lynch J, Lee K, Shih M, Lee J, Aslan M. Association of Race and Ethnicity with Prescriptions for Continuous Glucose Monitoring Systems Among a National Sample of Veterans with Diabetes on Insulin Therapy. Diabetes Technology & Therapeutics 2024, 26: 908-917. PMID: 39177775, DOI: 10.1089/dia.2024.0152.Peer-Reviewed Original ResearchVeterans with diabetesAssociation of raceCross-sectional analysis of dataU.S. Veterans Health AdministrationNational sample of veteransNational sampleInsulin therapyVeterans Health AdministrationSystem-level factorsSample of veteransNon-Hispanic patientsSelf-reported raceContinuous glucose monitoringCross-sectional analysisContinuous glucose monitoring useRate of prescriptionMultivariate mixed-effects modelAfrican American patientsLatino patientsHealth AdministrationAlaska NativesType 2 diabetesPercentage of patientsSignificant disparitiesMixed-effects modelsNational rollout of a medication safety dashboard to improve testing for latent infections among biologic and targeted synthetic disease‐modifying agent users within the Veterans Health Administration
Schmajuk G, Ware A, Li J, Tarasovsky G, Shiboski S, Barton J, Miller K, Mitchell H, Dana J, Reiter K, Wahl E, Rozenberg‐Ben‐Dror K, Hauser R, Whooley M. National rollout of a medication safety dashboard to improve testing for latent infections among biologic and targeted synthetic disease‐modifying agent users within the Veterans Health Administration. Health Services Research 2024, 60: e14363. PMID: 39056425, PMCID: PMC11782092, DOI: 10.1111/1475-6773.14363.Peer-Reviewed Original ResearchConceptsVeterans Affairs Healthcare SystemVA facilitiesVeterans Health AdministrationAudit log dataInterrupted time seriesPost-deploymentFrequency of sessionsWeeks post-deploymentFacility levelNational rolloutEHR dataHealth AdministrationHealthcare personnelHealthcare systemUnited States Veterans Affairs healthcare systemPercentage of patientsScreening dataEHRDashboard deploymentFacility personnelStudy periodSessionsScreeningUnited StatesFacilitiesUltracongruent Versus Posterior-Stabilized Polyethylene: No Difference in Anterior Knee Pain but Decreased Noise Generation
Lizcano J, Molloy I, Kohli M, Yakkanti R, Tarabichi S, Austin M. Ultracongruent Versus Posterior-Stabilized Polyethylene: No Difference in Anterior Knee Pain but Decreased Noise Generation. Journal Of The American Academy Of Orthopaedic Surgeons 2024, 33: 135-144. PMID: 39018667, DOI: 10.5435/jaaos-d-24-00379.Peer-Reviewed Original ResearchAnterior knee painPatient-reported outcome measure scoresOutcome measure scoresKnee painPosterior stabilizationKnee injuriesMeasure scoresGenerator questionnairePatient satisfactionCohort of patientsIndependent risk factorPercentage of patientsNo differencePrimary outcomeSatisfaction ratePolyethylene designsPainNo notable differenceKneeScoresPS cohortTKAOsteoarthritisPS insertionPatientsRegional variations in morbidity and mortality among neonates with intraventricular hemorrhage: a national database analysis
Sayeed S, Theriault B, Hengartner A, Serrato P, Sadeghzadeh S, Belkasim S, Ahsan N, Elsamadicy E, DiLuna M, Elsamadicy A. Regional variations in morbidity and mortality among neonates with intraventricular hemorrhage: a national database analysis. Child's Nervous System 2024, 40: 3571-3580. PMID: 38955900, DOI: 10.1007/s00381-024-06514-5.Peer-Reviewed Original ResearchNational Inpatient SampleIntraoperative variablesLong-term neurodevelopmental outcomesLow gestational ageMultivariate logistic regression analysisPermanent CSF shuntNational database analysisLow birth weightPercentage of patientsRetrospective cohort studyAssociated with decreased oddsImpact of insurance statusAssociated with reduced oddsMedian total costAssociated with mortalityLogistic regression analysisBackgroundIntraventricular hemorrhageNeonatal IVHGestational ageIntraventricular hemorrhageNeurodevelopmental outcomesCSF diversionCSF shuntingCost of admissionBirth weightP101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study
Wang Z, Yang M, Chao J, Martins B, Chuang C, Shumel B, Sierka D, Carboni M, Strober B. P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study. British Journal Of Dermatology 2024, 191: i63-i64. DOI: 10.1093/bjd/ljae090.128.Peer-Reviewed Original ResearchAtopic dermatitisEpisodes of itchingTreatment satisfactionMonth 1Disease controlClinical practiceProportion of patientsPatient survey studyPercentage of patientsSustained improvementFollow-up resultsPrescribed dupilumabGeneralized estimating equationsQuality of lifePatient support programmeSingle-armDupilumabSkin symptomsBaseline surveyPatientsSupport programmesPatient satisfactionPractice guidelinesStatistical significanceMonthsChart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart reviewQuality Improvement Initiative Enhances Outpatient Pediatric Pulmonology Follow-up for Premature Infants with Bronchopulmonary Dysplasia
Brumer E, Godse S, Chandrasekar L, Kizilirmak T, Blythe E, Gozzo Y, Peterec S, Kandil S, Grossman M, Chen L, Weiss P, Sheares B. Quality Improvement Initiative Enhances Outpatient Pediatric Pulmonology Follow-up for Premature Infants with Bronchopulmonary Dysplasia. Pediatric Quality And Safety 2024, 9: e736. PMID: 38854502, PMCID: PMC11161285, DOI: 10.1097/pq9.0000000000000736.Peer-Reviewed Original ResearchSevere bronchopulmonary dysplasiaBronchopulmonary dysplasiaPremature infantsFollow-upClassification of bronchopulmonary dysplasiaDiagnosis of bronchopulmonary dysplasiaYale-New Haven Children's HospitalBronchopulmonary dysplasia severityFollow-up of childrenPulmonary follow-upStandard treatment optionPercentage of patientsRespiratory-related morbidityPremature babiesInternational Classification of DiseasesAccuracy of diagnosisTreatment optionsCorrect diagnosisChildren's HospitalQuality improvement initiativesQuality improvement projectClassification of DiseasesMedical recordsPercentage of appointmentsElectronic medical recordsThe persistent benefits of decreasing default pill counts for postoperative narcotic prescriptions
Coppersmith N, Sznol J, Esposito A, Flom E, Chiu A, Yoo P. The persistent benefits of decreasing default pill counts for postoperative narcotic prescriptions. PLOS ONE 2024, 19: e0304100. PMID: 38833500, PMCID: PMC11149874, DOI: 10.1371/journal.pone.0304100.Peer-Reviewed Original ResearchConceptsOxycodone 5-mg tabletsPill countSurgical proceduresOpioid naive patientsOpioid prescribing habitsPostoperative narcotic prescriptionsQuantity of opioidsPercentage of patientsDay of surgeryClinicians' prescribing practicesElectronic medical record systemOpiate requirementsMorphine equivalentsChi-square testPostoperative opioidsOpioid prescriptionsNarcotic prescriptionsPrescription quantitiesOpioidAffiliated HospitalPrescribing habitsPatientsPrescribing practicesPersistent benefitsAcademic healthcare systemUsing an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.
Corvese L, Weiss C, Huie S, Zhou B, Deng Y, Gong G, Kunz P, Fischbach N. Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials. Journal Of Clinical Oncology 2024, 42: e13586-e13586. DOI: 10.1200/jco.2024.42.16_suppl.e13586.Peer-Reviewed Original ResearchClinical trialsCancer clinical trialsTrial enrollmentPercentage of patientsYale Cancer CenterClinical trial enrollmentLimitations of clinical trialsTreating providersEnrolling patientsCancer CenterUnique patientsBreast programPatientsPatient-matchedEnrollment ratesStudy-related activitiesScreening toolTrial participantsTrialsCancerOffice staffClinicEnrollmentLanguage barriersNon-English
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply